BioCentury
ARTICLE | Company News

CyDex Inc., TargeGen deal

July 5, 2004 7:00 AM UTC

TargeGen licensed rights to use CyDex's Captisol drug delivery technology to formulate TG 100-115, a kinase inhibitor in preclinical development to treat myocardial infarction. Captisol is a donut-sha...